Last update 23 Jan 2025

HA121-28

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
+ [1]
Target
EGFR x RET x VEGFR
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseRespiratory Diseases+ [1]
Active Indication
RET fusion-positive Non-Small Cell Lung CancerAdvanced Thyroid Gland Medullary CarcinomaThyroid Cancer, Medullary+ [1]
Inactive Indication
Advanced Bile Duct CarcinomaAdvanced biliary tract cancerEsophageal Carcinoma
Originator Organization
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
Active Organization
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationSpecial Review Project (CN)
Login to view timeline

Related

10
Clinical Trials associated with HA121-28
CTR20212821
/ RecruitingPhase 2
HA121-28片治疗RET融合阳性晚期非小细胞肺癌的单臂、多中心、开放性 II 期临床研究
[Translation] A single-arm, multicenter, open-label phase II clinical study of HA121-28 tablets in the treatment of RET fusion-positive advanced non-small cell lung cancer
NCT05117658
/ Unknown statusPhase 2
A Single-Arm, Multi-Centre, Open-Label Phase II Study of HA121-28 in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
NCT05072535
/ CompletedPhase 1
A Single-dose, Randomized, Open-label, Two-period Crossover, Phase I Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects
100 Clinical Results associated with HA121-28
Login to view more data
100 Translational Medicine associated with HA121-28
Login to view more data
100 Patents (Medical) associated with HA121-28
Login to view more data
100 Deals associated with HA121-28
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RET fusion-positive Non-Small Cell Lung CancerPhase 2
CN
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
10 Mar 2022
Advanced Thyroid Gland Medullary CarcinomaPhase 2
CN
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
13 Jul 2021
Thyroid Cancer, MedullaryPhase 2
CN
CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.
13 Jul 2021
Advanced Malignant Solid NeoplasmPhase 1
CN
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
19 Oct 2018
Advanced Bile Duct CarcinomaPreclinical
CN
CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.CSPC Zhongqi Pharmaceutical Technology (Tianjin) Co., Ltd.
22 Jun 2021
Advanced biliary tract cancerPreclinical
CN
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
27 May 2021
Esophageal CarcinomaDiscovery
CN
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.
29 Mar 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03994484 (ESMO 12021 | ESMO 22021)
ManualManual
Phase 1
HR-positive/HER2-low Solid Tumors
41
(dose-escalation part)
(qivfjeaohy) = wo dose-limiting toxicities (grade-3 anorexia; prolonged QTc interval) occurred at 800 mg kzabbksvas (vzhfwuzzxe )
View more
Positive
16 Sep 2021
(dose-expansion part)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free